Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

NCT06348134 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
HER2-positive Breast Cancer
Breast Cancer

Interventions

DRUG: Trastuzumab emtansine
DRUG: Pertuzumab Injection
DRUG: Docetaxel
DRUG: Tamoxifen
DRUG: Letrozole
DRUG: Goserelin

Sponsor

University of Chicago